CAS 1044515-88-9: Tralokinumab

Description:Tralokinumab is a monoclonal antibody that specifically targets interleukin-13 (IL-13), a cytokine involved in various inflammatory processes, particularly in allergic diseases and asthma. It is designed to inhibit the activity of IL-13, thereby reducing inflammation and associated symptoms. Tralokinumab is primarily used in the treatment of moderate to severe atopic dermatitis and has shown efficacy in improving skin clearance and reducing itch in affected patients. The substance is administered via subcutaneous injection and has a long half-life, allowing for less frequent dosing. Its mechanism of action involves binding to IL-13, preventing it from interacting with its receptors on target cells, which helps to modulate the immune response. As a biologic therapy, Tralokinumab is produced using recombinant DNA technology and is subject to rigorous quality control and regulatory standards to ensure safety and efficacy. Common side effects may include injection site reactions, headache, and upper respiratory infections, reflecting its immunomodulatory effects.

Formula:Unspecified

Synonyms:
Immunoglobulin G4, anti-(human interleukin 13) (human monoclonal CAT-354 heavy chain), disulfide with human monoclonal CAT-354 light chain, dimer
Tralokinumab
Adbry
CAT 354

Found 2 products.

Brand	Product data	Purity	Price range	Estimated delivery
	Tralokinumab REF: TM-T76704CAS: 1044515-88-9	SDS-PAGE:95% SEC-HPLC:99.99%	274.00 €~2,283.00 €	Wed 16 Apr 25
	Tralokinumab REF: 3D-CLA1139CAS: 1044515-88-9	- - -	To inquire	Mon 28 Apr 25